NASDAQ:LPTX

Leap Therapeutics - LPTX Stock Forecast, Price & News

$0.32

-0.01 (-3.05%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.29
▼
$0.34
50-Day Range: $0.32
▼
$0.72
52-Week Range: $0.29
▼
$1.95

Volume: 1.20 million shs
Average Volume: 553,981 shs
Market Capitalization: $31.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.80

Institutional Ownership

Leap Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 780.8% Upside
$2.80 Price Target
Short Interest: Bearish
9.06% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.01
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.47) to ($0.34) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

702nd out of 989 stocks

Pharmaceutical Preparations Industry

337th out of 480 stocks

3.5

Analyst's Opinion

Consensus Rating
Leap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.80, Leap Therapeutics has a forecasted upside of 780.8% from its current price of $0.32.
Amount of Analyst Coverage
Leap Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.06% of the outstanding shares of Leap Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Leap Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Leap Therapeutics has recently increased by 45.15%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Leap Therapeutics does not currently pay a dividend.
Dividend Growth
Leap Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LPTX.

2.2

News and Social Media Coverage

News Sentiment
Leap Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Leap Therapeutics this week, compared to 0 articles on an average week.
Search Interest
22 people have searched for LPTX on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.
MarketBeat Follows
6 people have added Leap Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Leap Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.50% of the stock of Leap Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 37.44% of the stock of Leap Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Leap Therapeutics are expected to grow in the coming year, from ($0.47) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Leap Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Leap Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Leap Therapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Stock News Headlines

March 24, 2023 | markets.businessinsider.com

Mizuho Securities Remains a Buy on Leap Therapeutics (LPTX)

March 24, 2023 | finanznachrichten.de

Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

March 25, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 20, 2023 | markets.businessinsider.com

Robert W. Baird Keeps Their Buy Rating on Leap Therapeutics (LPTX)

March 20, 2023 | americanbankingnews.com

Leap Therapeutics (NASDAQ:LPTX) PT Lowered to $2.00 at Mizuho

March 16, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Its Buy Rating for Leap Therapeutics (LPTX)

March 16, 2023 | finance.yahoo.com

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

March 16, 2023 | uk.finance.yahoo.com

Leap Therapeutics, Inc. (LPTX)

March 25, 2023 | Stansberry Research (Ad)

The gold catalyst we’ve waited for

If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.

January 25, 2023 | benzinga.com

SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigations

January 25, 2023 | finance.yahoo.com

Leap Therapeutics Shares Fall After Flame Biosciences Acquisition

January 24, 2023 | businesswire.com

LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders

January 19, 2023 | wsj.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. Buyout

January 18, 2023 | msn.com

HC Wainwright & Co. Maintains Buy Rating for Leap Therapeutics: Here's What You Need To Know

November 21, 2022 | finance.yahoo.com

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

November 16, 2022 | finance.yahoo.com

Leap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

November 7, 2022 | finance.yahoo.com

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

October 26, 2022 | finance.yahoo.com

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

October 19, 2022 | seekingalpha.com

LPTX Leap Therapeutics, Inc.

October 12, 2022 | finance.yahoo.com

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

August 16, 2022 | au.finance.yahoo.com

Leap Therapeutics Reports Second Quarter 2022 Financial Results

August 12, 2022 | finance.yahoo.com

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

July 21, 2022 | finance.yahoo.com

Do Institutions Own Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares?

July 19, 2022 | benzinga.com

Leap Therapeutics (NASDAQ:LPTX), Analyst Ratings, Price Targets, Predictions

May 19, 2022 | finance.yahoo.com

We're Keeping An Eye On Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Rate

May 13, 2022 | finance.yahoo.com

Leap Therapeutics Reports First Quarter 2022 Financial Results

April 9, 2022 | finance.yahoo.com

Shareholders in Leap Therapeutics (NASDAQ:LPTX) are in the red if they invested five years ago

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Company Calendar

Last Earnings: 3/24/2023
Today: 3/25/2023
Next Earnings (Estimated): 5/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LPTX
CUSIP: N/A
CIK: 1509745
Web: www.leaptx.com
Phone: (617) 714-0360
Fax: N/A
Employees: 36
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.80
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +780.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,590,000.00
Net Margins: N/A
Pretax Margin: -14,214.93%
Return on Equity: -59.23%
Return on Assets: -53.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.82
Quick Ratio: 6.82

Sales & Book Value

Annual Sales: $1.50 million
Price / Sales: 20.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.22 per share
Price / Book: 0.26

Miscellaneous

Outstanding Shares: 99,020,000
Free Float: 86,643,000
Market Cap: $31.48 million
Optionable: Not Optionable
Beta: 0.75

Key Executives

Doug E. Onsi
President, CEO, CFO, Secretary & Treasurer

Augustine J. Lawlor
Chief Operating Officer

Cynthia Sirard
Chief Medical Officer

Michael Haas
Head-Research

Jason S. Baum
Vice President & Head-Translational Medicine

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LPTX Stock - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings or view top-rated stocks.
What is Leap Therapeutics' stock price forecast for 2023?: 3 brokerages have issued 1-year target prices for Leap Therapeutics' shares. Their LPTX share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 780.8% from the stock's current price.
View analysts price targets for LPTX or view top-rated stocks among Wall Street analysts.
How have LPTX shares performed in 2023?: Leap Therapeutics' stock was trading at $0.45 at the beginning of the year. Since then, LPTX stock has decreased by 29.4% and is now trading at $0.3179.
View the best growth stocks for 2023 here.
When is Leap Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our LPTX earnings forecast.
How were Leap Therapeutics' earnings last quarter?: Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings results on Friday, March, 24th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.02.
What other stocks do shareholders of Leap Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK), VYNE Therapeutics (VYNE), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL).

What is Leap Therapeutics' stock symbol?: Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."
Who are Leap Therapeutics' major shareholders?: Leap Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (2.78%), Key Client Fiduciary Advisors LLC (1.36%), Element Capital Management LLC (1.17%), Millennium Management LLC (1.12%), Renaissance Technologies LLC (0.93%) and Knott David M Jr (0.85%).
View institutional ownership trends.
How do I buy shares of Leap Therapeutics?: Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Leap Therapeutics' stock price today?: One share of LPTX stock can currently be purchased for approximately $0.32.
How much money does Leap Therapeutics make?: Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $31.48 million and generates $1.50 million in revenue each year. The company earns $-40,590,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.
How can I contact Leap Therapeutics?: Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for the company is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com.

This page (NASDAQ:LPTX) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Leap Therapeutics - LPTX Stock Forecast, Price & News

Leap Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Leap Therapeutics (NASDAQ:LPTX) Stock

LPTX Stock News Headlines

LPTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

LPTX Stock - Frequently Asked Questions

Overall MarketRank^™